CM383 vs Trontinemab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Alzheimer's Disease

Shared mechanism: Amyloid-beta (monoclonal antibody) · full Alzheimer's Disease pipeline

CM383

Developed by Keymed Biosciences

Phase 1 in Alzheimer's Diseasemonoclonal antibody
Weak signal

NCT06412185 · Phase 1 · status unknown

This is a randomized, blinded, placebo-controlled study, but it is an early safety study in healthy volunteers rather than patients, and its primary measured outcome is safety rather than a disease outcome. Results have not yet been posted. Its registered primary outcome on ClinicalTrials.gov is "Adverse events". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: December 2026 · NCT06619613 (registry estimate)

No aligned efficacy figure on record for this race.

Trontinemab

Developed by Roche

Phase 3 in Alzheimer's Diseasebispecific antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: July 2027 · NCT04639050 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Alzheimer's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCM383Trontinemab
CDR-SB, change—Not reported—Trial running · NCT07170150
ADAS-Cog11, change—Not reported—Trial running · NCT07170150
ADCS-ADL, change—Not reported—Trial running · NCT07170150
MMSE, change—Not reported—Trial running · NCT07170150
Amyloid PET, change (centiloids)—Not reported—Trial running · NCT07170150

CDR-SB, change

CM383
—Not reported
Trontinemab
—Trial running · NCT07170150

ADAS-Cog11, change

CM383
—Not reported
Trontinemab
—Trial running · NCT07170150

ADCS-ADL, change

CM383
—Not reported
Trontinemab
—Trial running · NCT07170150

MMSE, change

CM383
—Not reported
Trontinemab
—Trial running · NCT07170150

Amyloid PET, change (centiloids)

CM383
—Not reported
Trontinemab
—Trial running · NCT07170150
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

CM383: no structured comparison results are available for Alzheimer's Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. CM383: 0 of 4 rows · Trontinemab: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricTrontinemab
Dropout rate
0%7.2 mg/kga
NCT04023994 · Phase 1 · registry result, not featured evidence
show 4 more results
0%3.6 mg/kg
NCT04023994 · Phase 1 · registry result, not featured evidence
16.7%1.2 mg/kg
NCT04023994 · Phase 1 · registry result, not featured evidence
50%0.4 mg/kg
NCT04023994 · Phase 1 · registry result, not featured evidence
25%0.1 mg/kg
NCT04023994 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—7.2 mg/kga
NCT04023994 · Phase 1 · registry result, not featured evidence
show 4 more results
—3.6 mg/kg
NCT04023994 · Phase 1 · registry result, not featured evidence
—1.2 mg/kg
NCT04023994 · Phase 1 · registry result, not featured evidence
—0.4 mg/kg
NCT04023994 · Phase 1 · registry result, not featured evidence
—0.1 mg/kg
NCT04023994 · Phase 1 · registry result, not featured evidence
Serious AEs
0%7.2 mg/kga
NCT04023994 · Phase 1 · registry result, not featured evidence
show 4 more results
0%3.6 mg/kg
NCT04023994 · Phase 1 · registry result, not featured evidence
0%1.2 mg/kg
NCT04023994 · Phase 1 · registry result, not featured evidence
0%0.4 mg/kg
NCT04023994 · Phase 1 · registry result, not featured evidence
0%0.1 mg/kg
NCT04023994 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
7.2 mg/kga
infusion related reaction 100% (placebo 10%)
headache 50% (placebo 50%)
injection site extravasation 16.7% (placebo 0%)
NCT04023994 · Phase 1 · registry result, not featured evidence
show 4 more results
3.6 mg/kg
infusion related reaction 83.3% (placebo 10%)
nausea 33.3% (placebo 30%)
back pain 16.7% (placebo 0%)
NCT04023994 · Phase 1 · registry result, not featured evidence
1.2 mg/kg
headache 83.3% (placebo 50%)
back pain 50% (placebo 0%)
nausea 50% (placebo 30%)
NCT04023994 · Phase 1 · registry result, not featured evidence
0.4 mg/kg
back pain 25% (placebo 0%)
headache 25% (placebo 50%)
arthralgia 0% (placebo 10%)
NCT04023994 · Phase 1 · registry result, not featured evidence
0.1 mg/kg
back pain 75% (placebo 0%)
arthralgia 0% (placebo 10%)
chills 0% (placebo 0%)
NCT04023994 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CM383's landscape · Trontinemab's landscape